Cselényi Zsolt, Farde Lars
Department of Clinical Neuroscience, PET Centre, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Neuroscience, AZ Translational Science Centre, Karolinska Institutet, Stockholm, Sweden.
J Cereb Blood Flow Metab. 2015 Sep;35(9):1485-93. doi: 10.1038/jcbfm.2015.66. Epub 2015 Apr 15.
Longitudinal positron emission tomography (PET) imaging of beta-amyloid is used in basic research and in drug efficacy trials in Alzheimer's disease (AD). However, the extent of amyloid accumulation after clinical onset is not fully known. Importantly, regional PET data are typically quantified using the standardized uptake value ratio (SUVR), which according to simulations is sensitive to changes in regional cerebral blood flow (rCBF). We aimed to better understand the potentials of longitudinal amyloid imaging by disentangling the influence of blood flow on SUVR using experimental data. [18F]AV-45 PET data from 101 subjects, ranging from cognitively normal to AD patients, in the Alzheimer's Disease Neuroimaging Initiative were extracted. The relationship between global cortical distribution volume ratio, indicator of rCBF (R1), and SUVR was examined using multilinear regression. There was a significant effect of rCBF on SUVR. The effect increased by disease severity. Results suggest that changes in rCBF can produce apparent changes in SUVR in AD. Therefore, future longitudinal studies should measure amyloid changes in a way not sensitive to this effect, ideally using quantitative PET imaging. Furthermore, the results suggest no true accumulation beyond clinical onset and highlight the risks of longitudinal amyloid imaging in drug trials in AD.
β-淀粉样蛋白的纵向正电子发射断层扫描(PET)成像用于阿尔茨海默病(AD)的基础研究和药物疗效试验。然而,临床发病后淀粉样蛋白积累的程度尚不完全清楚。重要的是,区域PET数据通常使用标准化摄取值比率(SUVR)进行量化,根据模拟结果,该比率对区域脑血流量(rCBF)的变化敏感。我们旨在通过利用实验数据厘清血流对SUVR的影响,从而更好地理解纵向淀粉样蛋白成像的潜力。从阿尔茨海默病神经成像计划中提取了101名受试者的[18F]AV-45 PET数据,这些受试者涵盖了从认知正常到AD患者的范围。使用多线性回归研究了全球皮质分布体积比率、rCBF指标(R1)和SUVR之间的关系。rCBF对SUVR有显著影响。这种影响随着疾病严重程度的增加而增强。结果表明,rCBF的变化可在AD中导致SUVR出现明显变化。因此,未来的纵向研究应以对这种影响不敏感的方式测量淀粉样蛋白变化,理想情况下使用定量PET成像。此外,结果表明临床发病后并无真正的积累,并突出了AD药物试验中纵向淀粉样蛋白成像的风险。